PPCB — Propanc Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517681 ·
Last close
$1.88
Market Cap
$1.94M
52W High
$315.00
52W Low
$1.63
ADV30
36,167
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,457,050 | -4,573,242 | 12,779,912 | 832,006 | 3,378,251 |
| Mar 2026 | 0 | — | -6,400,221 | -6,360,336 | 14,333,780 | 443,702 | 3,505,895 |
| Dec 2025 | 0 | — | -3,654,734 | -3,091,394 | 15,111,532 | 561,237 | 3,659,267 |
| Sep 2025 | 0 | — | -4,673,564 | -4,837,738 | 17,975,681 | 602,737 | 3,614,514 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,682,635
Investing CF
$-4,933
Financing CF
$6,457,298
CapEx
$-4,933
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-336.75
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-144,484,230
Inventory
—
Receivables
$13,694
ST Investments
—
EBIT TTM
$-18,432,171
Pretax Income TTM
$-18,862,710
Interest Exp TTM
$430,539
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -18,185,569 | -18,862,710 | 12,779,912 | 3,378,251 | 9,401,661 | -5,682,635 |
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -1,536,049 | -1,820,528 | 72,365 | 3,851,424 | -3,779,059 | -935,118 |
| Jun 2023 | 0 | -1,776,645 | -2,660,566 | 60,300 | 3,177,507 | -3,117,179 | -1,105,251 |
| Jun 2022 | 0 | -1,990,870 | -2,658,087 | 81,651 | 3,105,300 | -3,023,649 | -1,436,304 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-18,862,710
OpCashFlow TTM
—
Assets (Latest)
$14,333,780
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XRTX | XORTX Therapeutics Inc. | $1.93M | $1.06 | — |
| JAGX | Jaguar Health, Inc. | $1.96M | $0.38 | — |
| ACUT | Accustem Sciences Inc. | $1.90M | $0.12 | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $2.00M | $1.52 | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $1.88M | $0.53 | — |
News headlines (Yahoo Finance, 1h cache)
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
2026-11-02 13:30 · Yahoo
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
2026-10-30 12:30 · Yahoo
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
2026-10-28 12:30 · Yahoo
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
2026-10-26 12:30 · Yahoo
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
2026-10-22 20:24 · Yahoo
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
2026-10-22 12:30 · Yahoo
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
2026-10-16 12:36 · Yahoo
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
2026-10-14 12:30 · Yahoo
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
2026-09-29 12:30 · Yahoo
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
2026-09-22 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.